Annual report pursuant to Section 13 and 15(d)

Consolidated Balance Sheets

v3.20.4
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Current Assets    
Cash and cash equivalents $ 6,227 $ 15,045
Prepaid expenses and other current assets 1,707 1,381
Total Current Assets 7,934 16,426
Property and equipment, net 174 367
Right-of-Use Asset 279 419
Deposits and other assets 23 23
Total Assets 8,410 17,235
Current Liabilities:    
Accounts payable 886 2,315
Accrued expenses 925 1,776
Accrued employee benefits 868 935
Lease liability 287 249
Total Current Liabilities 2,966 5,275
Lease liability - Long term 186 473
Total Liabilities 3,152 5,748
Commitments and Contingencies
Series A convertible preferred stock, $0.001 par value; 10,000,000 shares authorized; 120,000 issued and outstanding 12,798 12,544
Stockholders' Deficit:    
Series B convertible preferred stock, $0.0001 par value; 10,000,000 shares authorized, 3,973 issued and outstanding at December 31,2020 and 7,638 issued and outstanding at December 31, 2020 2,477 4,761
Common stock, $0.001 par value; 200,000,000 shares authorized, 29,252,253 issued and 29,249,925 outstanding at December 31,2020 and 16,808,758 issued and 16,806,430 outstanding at December 31,2019 29 17
Additional paid-in capital 240,821 232,580
Accumulated deficit (248,094) (235,537)
Total Synthetic Biologics, Inc. and Subsidiaries (Deficit) Equity (4,767) 1,821
Non-controlling interest (2,773) (2,878)
Total Stockholders' Deficit (7,540) (1,057)
Total Liabilities and Stockholders' Deficit $ 8,410 $ 17,235